Search research articles
Contact Us
Filters
Showing results (181-190 of 193) with videos related to
Page
of 20
Sort By:
Bone Marrow Transplantation
|
April 13, 2022
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
Francesca Bonifazi, Chiara Pavoni, Jacopo Peccatori, et al.
Hematological Oncology
|
October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort
Michele Merli, Isacco Ferrarini, Francesco Merli, et al.
Blood
|
March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis
Barbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Cancer
|
March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
Francesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2013
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial
Roelof Willemze, Stefan Suciu, Giovanna Meloni, et al.
Cancer
|
January 24, 2023
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia
Elisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
Blood Cancer Journal
|
May 3, 2023
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
Francesca Palandri, Elena M Elli, Giuseppe Auteri, et al.
Blood Advances
|
February 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351
Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Blood Advances
|
December 5, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351
Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Hemasphere
|
October 16, 2020
SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience
Sandra Mossuto, Enrico Attardi, Francesco Alesiani, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 193) with videos related to
Sort By:
Page
of 20
Bone Marrow Transplantation
|
April 13, 2022
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
Francesca Bonifazi, Chiara Pavoni, Jacopo Peccatori, et al.
Hematological Oncology
|
October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort
Michele Merli, Isacco Ferrarini, Francesco Merli, et al.
Blood
|
March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis
Barbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Cancer
|
March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
Francesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2013
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial
Roelof Willemze, Stefan Suciu, Giovanna Meloni, et al.
Cancer
|
January 24, 2023
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia
Elisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
Blood Cancer Journal
|
May 3, 2023
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
Francesca Palandri, Elena M Elli, Giuseppe Auteri, et al.
Blood Advances
|
February 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351
Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Blood Advances
|
December 5, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351
Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Hemasphere
|
October 16, 2020
SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience
Sandra Mossuto, Enrico Attardi, Francesco Alesiani, et al.
Page
of 20